Welcome to the first issue of Neurotech Weekly — our roundup of the funding, launches, and research that actually matter in consumer-accessible neurotechnology. No hype, no sci-fi headlines we can’t back up. Just the signal.
This week’s theme writes itself: non-invasive brain tech is having a regulatory moment, the money chasing brain-computer interfaces is getting harder to ignore, and the line between “wellness gadget” and “medical device” is blurring fast. Here’s what we’re watching.
The headline: a prescription brain-stimulation device is coming home
The biggest story in the space right now isn’t a brain implant — it’s a headband you can use in your bedroom. Flow Neuroscience’s FL-100 has become the first at-home, prescription transcranial direct current stimulation (tDCS) device cleared by the FDA for adults with moderate-to-severe major depressive disorder, either on its own or alongside other treatment, and it’s rolling out to US patients through 2026. (Medical Economics, Patient Care Online)
Why it matters: tDCS — applying a weak electrical current to the scalp to nudge activity in the prefrontal cortex — has been a biohacker curiosity for years. A formal FDA clearance moves it out of the gray zone of DIY brain-zapping and into a supervised, prescription pathway. More than 55,000 people across Europe, the UK, Switzerland, and Hong Kong have already used the system. (Patient Care Online)
The balanced take: this is a real milestone, not a miracle. The clearance is specifically for moderate-to-severe depression in people who aren’t treatment-refractory, it requires a clinician’s prescription, and — as one IEEE Spectrum overview noted — neurostimulation tends to offer symptom relief rather than a permanent cure. (IEEE Spectrum) tDCS has 25+ years of research behind it, but historically the results across studies have been heterogeneous. What changed here is the strength of the evidence package (more on that below), not the underlying physics. If you’ve been tempted by a cheap “brain stimulator” online, this is the opposite of that: regulated, supervised, and indication-specific.
Funding & deals: the money is concentrating, not spreading
The capital flowing into neurotech is real, but it’s pooling around a narrow set of bets.
- Q1 2026 was the strongest quarter on record for neurotech funding — roughly $976M across eight deals, led by BrainCo, Merge Labs, Science Corporation, and Cognito Therapeutics. That’s about double Q4 2025. Notably, the total wasn’t propped up by a single mega-round this time. (New Market Pitch)
- Brain-computer interfaces are eating the lion’s share. Across the last five quarters, BCI startups captured roughly three-quarters of all disclosed neurotech capital — even though neuromodulation devices account for more individual deals. Investors are concentrating on a few interface platforms rather than spreading bets across the field. (New Market Pitch)
- Merge Labs — Sam Altman’s non-invasive BCI startup — emerged from stealth in January with a $252M round led by OpenAI at an $850M valuation. Its pitch: interface with neurons using molecules and ultrasound instead of electrodes. (TechCrunch) It’s still very early-stage, but it’s a signal that the most AI-adjacent money now sees the brain as the next frontier.
- Neurosoft Bioelectronics (an EPFL spinout based in Geneva) closed a $7.5M oversubscribed seed round, bringing its total past $20M. Its soft, stretchable electrodes sit on the surface of the cortex without penetrating brain tissue, and the company says it’s already tested the platform in 10 patients. (Venturelab) A nice reminder that not all of European neurotech is invisible — even if the continent still raises far less than the US and China.
Products & tools: the AI-integration angle gets real
For the consumer EEG crowd, the most interesting product story is about plumbing, not hardware.
The Neurosity Crown is, as of 2026, the only consumer EEG device shipping with an official, vendor-supported Model Context Protocol (MCP) server out of the box — meaning AI assistants like Claude or ChatGPT can read your real-time brain data through a standardized protocol without you building the middleware yourself. (Neurosity) Whatever you think of brain-data-meets-LLM as a concept (and there are legitimate privacy questions worth a future explainer), it’s the clearest example yet of where consumer neurotech and AI are converging.
For context, the Muse S Athena remains the more approachable option — the first consumer headband to pair EEG with fNIRS (blood-oxygenation) sensing — but its data lives inside InteraXon’s subscription app, with no native AI hook. (IEEE Spectrum) Different philosophies: polished walled garden vs. open, developer-first platform. We covered the full three-way comparison in our EEG headbands guide.
Research watch: the trial behind the Flow headlines
The FDA clearance above rests on a randomized controlled trial — described as the largest of its kind — published in Nature Medicine. By the end of the 10-week study, 58% of patients reached remission, and active stimulation produced roughly two to three times the remission and response rates of sham, with mild, transient side effects. (Medical Economics, HMP Global)
A few things worth holding in mind before you treat “58% remission” as settled science: it’s a single (if large) trial, the comparison is against sham rather than against gold-standard antidepressants or TMS, and remission at 10 weeks tells us little about durability. That’s not a knock on the result — it’s how to read any single trial responsibly. The honest summary: this is among the strongest evidence tDCS has produced for depression, and it’s enough to justify a supervised clinical pathway. It is not yet enough to call it a first-line treatment.
Company spotlight: Flow Neuroscience
It’s hard to spotlight anyone else this issue. Flow Neuroscience sits exactly at the intersection we care about — non-invasive neurostimulation, mental health, and a consumer-friendly form factor — and it just did the hardest thing in this space: clear a regulator with real evidence. The Swedish company has spent years building a tDCS platform around a smartphone app and a forehead-mounted headset targeting the dorsolateral prefrontal cortex, and it’s now positioned to bring that into US homes by prescription. (Medical Economics)
What we’ll be watching: pricing and insurance coverage once it launches, whether Flow expands into anxiety, PTSD, or other indications it has hinted at, and whether FDA clearance pulls the rest of the at-home neurostimulation market toward the same evidentiary bar — or just gives lower-quality “brain zapper” gadgets a halo they haven’t earned.
The bottom line
The through-line this week is legitimacy. Non-invasive brain tech is graduating from forums and Kickstarters into regulated medicine and nine-figure rounds. That’s good for the field — and it raises the bar for everyone making claims about what these devices can do. We’ll keep separating the validated from the hopeful.
That’s it for issue #1. If you found this useful, subscribe to get Neurotech Weekly in your inbox — one signal-rich roundup, no noise.
AnbiTech covers consumer-accessible neurotechnology for information purposes only. Nothing here is medical advice. Neurostimulation and neurofeedback devices vary widely in their evidence base; talk to a qualified clinician before starting any treatment for a mental health condition.